COPD drug breztri under Real-World watch in korea
NCT ID NCT07570394
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 600 adults in Korea who have been prescribed Breztri for COPD, a long-term lung disease. Researchers want to see how safe the drug is in everyday use and whether it works as expected. Participants will take Breztri as their doctor prescribes, and the study will track any side effects and changes in lung function over 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care
- Could your own lung cells heal COPD? a new stem cell trial aims to find out
- Breathing easy: dynamic x-rays may spot COPD faster and safer
- Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer
- Could a simple screening strategy uncover hidden TB in COPD patients?
- Routine blood test may reveal hidden clues in COPD emergencies